The system uses synthetic probes that bind to molecules of interest and then pass through solid-state nanopores, enabling detection of the target molecules.
Under the terms of the deals, Illumina and Monsanto will have access to NRGene's genome assembly and analysis technologies for ag-bio research projects.
CRISPR/Cpf1 can serve as an alternative or even complementary genome editing technology to CRISPR/Cas9, which Monsanto has also licensed from the Broad.
The technology is based on engineered zinc finger DNA-binding proteins, which bind to specific functional domains to create transcription factors capable of activating or repressing target genes.
St. Jude Children's Research Hospital scientists have treated infants with X-linked severe combined immunodeficiency using gene therapy in an early phase study.
In Nature this week: a genomic analysis of the snailfish Pseudoliparis swirei, ancient DNA analysis gives insight into the introduction of farming to England, and more.
